Antibodies to a high-risk type of human papilloma virus (HPV16) could help detect oropharyngeal cancer several years before the clinical onset of the disease, reveals a new study from the International Agency for Research on Cancer (IARC) in cooperation with the German Cancer Research Center (DKFZ) and the United States National Cancer Institute (NCI) in an article published online today by the Journal of Clinical Oncology. Read more here.
No comments:
Post a Comment